Journal article · 2025 · Open access

From biomarkers to drug delivery: advances in extracellular vesicles in cancer diagnosis and targeted therapy

Linnea Lindqvist, Felix Andersson

Clinical and translational reports, 51–61 · Published 15 June 2025 · DOI 10.58832/ctr.2025.6.6.5

Free PDFView at the publisherCite this paper

In brief

“From biomarkers to drug delivery: advances in extracellular vesicles in cancer diagnosis and targeted therapy” is a 2025 journal article by Linnea Lindqvist and Felix Andersson, published in Clinical and translational reports. OpenAlex counts 0 citations as of 15 November 2026. It is open access: the full text is free to read at Clinical and translational reports.

Citations
0
Authors
2

Abstract

Extracellular vesicles (EVs), lipid-bilayer nanoparticles secreted by diverse cell types, have emerged as pivotal mediators in cancer progression through intercellular communication. These vesicles encapsulate oncogenic biomolecules—including proteins, nucleic acids, and metabolites—enabling the reprogramming of recipient cells to foster tumor initiation, angiogenesis, immune evasion, and metastatic niche formation. Tumor-derived EVs (TDEVs) reflect parental cell molecular profiles, offering non-invasive biomarkers for cancer diagnosis. Their stability in bodily fluids and enrichment of tumor-specific markers, such as mutant DNA, oncogenic miRNAs, and immunosuppressive ligands, surpass conventional circulating biomarkers in sensitivity and specificity, positioning EVs as promising tools for liquid biopsy. In addition to their diagnostic potential, EVs have dual roles as therapeutic targets and drug delivery vehicles. TDEVs promote chemoresistance by transferring drug efflux pumps, pro-survival RNAs, and immunosuppressive factors, but their inherent biocompatibility and targeting capabilities make them ideal nanocarriers. In preclinical models, engineered EVs loaded with chemotherapeutics, siRNA, or CRISPR-Cas9 components exhibit enhanced tumor accumulation and reduced off-target toxicity. Surface modifications, such as peptide conjugation or antibody integration, further improve their homing specificity. This review synthesizes advances in EV biology, diagnostic applications, and therapeutic innovations, highlighting their translational potential in oncology. By combining mechanistic insights with translational opportunities, we highlight the evolving promise of EVs as versatile platforms for cancer management.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Lindqvist, L., & Andersson, F. (2025). From biomarkers to drug delivery: advances in extracellular vesicles in cancer diagnosis and targeted therapy. Clinical and translational reports, 51–61. https://doi.org/10.58832/ctr.2025.6.6.5

MLA 9

Lindqvist, Linnea, and Felix Andersson. “From biomarkers to drug delivery: advances in extracellular vesicles in cancer diagnosis and targeted therapy.” Clinical and translational reports, no. 1, 2025, pp. 51–61. https://doi.org/10.58832/ctr.2025.6.6.5.

Chicago

Lindqvist, Linnea and Felix Andersson. 2025. “From biomarkers to drug delivery: advances in extracellular vesicles in cancer diagnosis and targeted therapy.” Clinical and translational reports (1): 51–61. https://doi.org/10.58832/ctr.2025.6.6.5.

Harvard

Lindqvist, L. and Andersson, F. (2025) ‘From biomarkers to drug delivery: advances in extracellular vesicles in cancer diagnosis and targeted therapy’, Clinical and translational reports, pp. 51–61. doi:10.58832/ctr.2025.6.6.5.

IEEE

L. Lindqvist and F. Andersson, “From biomarkers to drug delivery: advances in extracellular vesicles in cancer diagnosis and targeted therapy,” Clinical and translational reports, no. 1, pp. 51–61, 2025, doi: 10.58832/ctr.2025.6.6.5.

BibTeX

@article{lindqvist2025from,
  title     = {{From biomarkers to drug delivery: advances in extracellular vesicles in cancer diagnosis and targeted therapy}},
  author    = {Lindqvist, Linnea and Andersson, Felix},
  journal   = {Clinical and translational reports},
  year      = {2025},
  number    = {1},
  pages     = {51--61},
  doi       = {10.58832/ctr.2025.6.6.5},
  url       = {https://doi.org/10.58832/ctr.2025.6.6.5}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease

  • extracellular vesicles
  • tumor-derived extracellular vesicles
  • cancer diagnosis
  • liquid biopsy
  • tumor markers
  • targeted drug delivery
  • nanocarriers
  • chemoresistance

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Lindqvist, L., & Andersson, F. (2025). From biomarkers to drug delivery: advances in extracellular vesicles in cancer diagnosis and targeted therapy. Clinical and translational reports, 51–61. https://doi.org/10.58832/ctr.2025.6.6.5

How many times has this paper been cited?

0 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Clinical and translational reports.

Who wrote this paper?

Linnea Lindqvist, Felix Andersson.

What is the DOI of this paper?

10.58832/ctr.2025.6.6.5. The permanent link is https://doi.org/10.58832/ctr.2025.6.6.5.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.